 |
 |
 |
| Home > Client Services > Client List > Lundbeck Limited |
Lundbeck Limited Jobs ProfileThis profile is a brief introduction for people seeking employment in pharmaceutical graduate jobs, pharmaceutical nurse advisors, pharmaceutical sales jobs, pharmaceutical training jobs, pharmaceutical sales management jobs, pharmaceutical marketing jobs, pharmaceutical executive jobs, or pharmaceutical clinical research associates who may be considering working for Lundbeck Limited. Company Overview Specialists in Psychiatry, Pioneers in Neurology As a pharmaceutical manufacturer, Lundbeck is unique. Our vision is to become a world leader in the development of pharmaceuticals for psychiatric and neurological disorders. We are already pioneers of new treatments and approaches. Our mission is to improve quality of life for those suffering from psychiatric and neurological disorders. We aim to specialise in the large-scale commercial manufacture of Lundbeck's strategic products, providing a top quality service, with the highest degree of security of supply, at a competitive price.
Our key focus areas: - Depression: Cipralex/ Lexapro(escitalopram) and Cipramil/ Celexa (citalopram).
|
Psychiatry Key Account Executive Location: North East London GP/ Hospital Representative Location: Fife/Forth Valley (6 month secondment cover) GP/ Hospital Representative Location: Essex Neurology Key Account Executive Location: Central, North West and West London, Berkshire, Ox GP/ Hospital Representative Location: Lothian & Lanarkshire Psychiatry Key Account Executive Location: North West London & Herts GP/ Hospital Representative Location: Surrey Psychiatry Key Account Executive Location: North West London News Lundbeck and Teva announce Azilect results Lundbeck and its partner Teva Pharmaceutical Industries have announced the results of the phase III Adagio study of Azilect (rasagiline) in Parkinson's disease patients. Lundbeck 'achieves strong performance' Lundbeck has published its financial results for the second quarter of the 2008 fiscal year, with the company reporting an "exceptionally" strong performance for the period. Lundbeck and Myriad to further investigate Flurizan trials Lundbeck and Myriad have announced they are to explore further the results from the phase III trial of Flurizan (tarenflurbil). Lundbeck-supported PTSD trial completes recruitment One of the largest-ever studies into the prevention of post-traumatic stress disorder (PTSD) has completed the recruitment stage, it was announced this week. Lundbeck and Myriad agree Flurizan European commercialisation rights Lundbeck has acquired from Myriad Genetics the commercialisation rights to Flurizan, an Alzheimer's treatment, currently in its phase III development. | ||||||||
